ChemoCentryx, Inc.
Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor
Last updated:
Abstract:
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of a central nervous system cancer.
Status:
Application
Type:
Utility
Filling date:
19 Mar 2020
Issue date:
24 Sep 2020